Thank you, Shiraz. Given the current competitive sponsor finance cash flow market, the flexibility offered by our commercial finance strategies enables us to source attractive investment opportunities away from this competitive cash flow market. We take a fundamental bottom-up approach to our portfolio construction based on the relative risk-adjusted return profile across our investment verticals. At quarter end, on a fair value basis, the comprehensive investment portfolio consisted of approximately $3.2 billion of senior secured loans to over 850 borrowers. The average exposure per borrower is $3.7 million. Measured at fair value, over 98% of our portfolio consisted of senior secured loans, with just under 97% invested in first lien loans, including investments in the SSLP attributable to the company and only 0.2% was invested in second lien cash flow loans. With the remaining 1.2% of the portfolio invested in second lien asset-based loans. Our specialty finance investments account for approximately 78% of the comprehensive portfolio. With just over 22% invested in first lien cash flow loans to upper mid-market sponsor-backed companies. We believe this defensive portfolio construction positions us well and provides a differentiated risk return profile relative to sponsor finance only portfolios. At quarter end, our weighted average yield on the comprehensive portfolio was 11.8%. Our portfolio credit quality remains strong. At quarter end, the weighted average investment risk rating was just under 2 based on our 1 to 4 risk rating scale, with 1 representing the least amount of risk. Over 98% of the portfolio is rated 2 or higher at quarter end. Additionally, 99.4% of the portfolio on a cost basis and 99.6% on a fair value basis was performing with only one investment on nonaccrual. Now, let me touch on each of our 4 investment verticals. Sponsored finance or cash flow lending. In this business, we originated first lien senior secured loans to upper mid-market companies in noncyclical industries, such as health care, business services and financial services. This has helped to mitigate the impact on the portfolio from cyclical economic factors. At quarter end, our sponsor finance cash flow portfolio was $714 million, including senior loans in our SSLP, representing 22.4% of the comprehensive portfolio. It was invested across 45 borrowers with approximately 99% of portfolio invested in first lien loans. Our borrowers have a weighted average EBITDA of approximately $132 million, EBITDA of $65 million and carry low LTVs of just over 42%. Sponsor Finance, the average EBITDA and revenue growth continues to be positive across our portfolio companies. Overall, our borrowers have successfully managed the transition to an environment with higher cost of capital, as well as inflationary premiums. The weighted average interest coverage for our sponsor cash flow loans has been stable at approximately 1.8 times. Additionally, only 1.7% of our third quarter gross income is in the form of capitalized PIK [ph] interest from cash flow borrowers, resulting from amendments. We believe these healthy credit metrics are the result of the diversity of our investment portfolio across private credit strategies. And our focus in sponsor finance on recession-resilient industries with high recurring free cash flow. While M&A has picked up in the second half of this year, activity levels are still well below the historic norm. This has caused much of the private debt activity to remain centered on repricings and dividend recaps. With the resulting spread compression and weaker structural protections, we are remaining highly selective in our cash flow investments. However, we are optimistic that the sponsor finance conditions will improve next year as sponsors seek to return capital to their LPs through exits. During the quarter, we made investments of $14.5 million in sponsor first lien loans and experienced repayments of just under $39 million. Michael mentioned sponsor finance deal flow continues to be muted due to the lower M&A volume. However, there are pockets of opportunities in our defensive sectors to invest at attractive risk-adjusted returns. At quarter end, the weighted average yield on our cash flow portfolio was 11.1%. Now let me turn to our specialty finance segments. Across the board, the credit quality of these loans continues to be solid with attractive LTVs supported by meaningful collateral. I'll first discuss our ABL portfolio. At quarter end, this portfolio totaled $1.1 billion, representing 35% of our total portfolio. It was invested in 262 different borrowers. Weighted average asset level yield was 14.4%. We continue to see an increase in the opportunity set for ABL resulting in a strong pipeline heading into year-end. Money center and regional domestic banks have been pulling back from the ABL market, creating an attractive opportunity for our team. Additionally, bank's ability to pledge asset-based loans or factoring loans as collateral for borrowing in the Fed has been reduced. SLR is positioned to collaborate with banks who are shifting their ABL strategies in reaction to these challenges. Our recent acquisition of the loan portfolio and servicing platform from Webster Commercial Services is an example of this type of opportunity. We're currently involved in other strategic discussions regarding either purchasing portfolios, joint ventures or referral programs. Additionally, we'll continue to see opportunities to provide ABL structured facilities to traditional cash flow borrowers who are facing liquidity pressures. Borrowers who have traditionally accessed the cash flow market are now more receptive to SLRs ABL solutions to provide working capital financing. These ABL facilities far about working capital assets from our borrower into a borrowing base that supports an incremental ABL facility ahead of their cash flow facility and provides additional liquidity for our borrowers. For the third quarter, we had $244 million of new ABL investments, including the Webster acquisition and repayments of $107 million. Turning to equipment finance. At quarter end, this portfolio totaled $1.1 billion, representing a third of our comprehensive portfolio with facilities across 540 borrowers. Credit profile of this portfolio continues to be stable. Weighted average asset level yield was 9.4%. During the third quarter, we originated $138 million of new assets with the majority of this coming from our business that provides leases to investment-grade borrowers for their mission-critical equipment. We had repayments of approximately $104 million. Our investment pipeline has expanded in conjunction with the disruption caused by last year's regional bank failures as well as the expansion of our vendor finance program. Now let me turn to Life Sciences. At quarter end, this portfolio totaled $267 million. Approximately 90% of the portfolio is comprised of investments in borrowers that have over 12 months of cash runway. Additionally, all of our portfolio companies have revenues with at least one product in commercialization stage, which significantly derisks our life science investment. These investments represented 8.4% of the total portfolio for the third quarter and contributed over 25% of our gross investment income. The life science industry continues to be somewhat challenged, with 28% of the deals to date being invested in down or flat rounds, which is the highest level in recent history. Many small cap and private biotech values have remained significantly lower than their pre Silicon Valley Bank collapsed highs and over $300 billion of VC dry powder has remained mostly on the sidelines waiting for valuations to reach a better equilibrium, particularly in later stage development companies where we invest. While SLR's portfolio has held up well, in part due to our focus on late-stage post-commercialization life science companies, there has been an increase in defaults in life science portfolios due to weaker lender protections that prevailed in the market prior to the collapse of Silicon Valley Bank. A forward-looking rate environment should result in a more normalized life science lending activity, but it will also slow the process, and we anticipate current conditions to persist for at least another couple of quarters. Venture debt financing in healthcare-related IT service companies has been active. But due to the lack of IP protection and other collateral that we require, SLR has remained on the sidelines. In addition to sourcing new opportunities in late-stage drug development and device companies, we remain focused on supporting and in some cases, expanding our existing portfolio of borrower relationships. By keeping healthy life science credits longer and increasing our credit facilities to finance their growth, we have been able to maintain meaningful exposure to this asset class during a challenging time for the life science industry broadly, while maintaining a comfortable level of diversity. During the third quarter, the team funded $1 million of new facilities and had $78 million of repayments. At quarter end, the weighted average yield on our life science portfolio was 12.6%, including potential success fees, however, excluding any potential warrant gains. With early signs of improvement in the life science market, we've seen a modest uptick in private and public equity valuations as well as in our investment pipeline. Given our ability to allocate capital to the best risk-reward opportunities across our various private credit asset classes, we have the luxury of being highly selective as we look to deploy capital in life sciences, while still generating positive originations across the entire platform. Lastly, let me touch on our SSLP. During the quarter, SLRC earned $1.9 million from SSLP, representing a 15.7% annualized yield, consistent with the prior quarter. At quarter end, it had a fair value of $204 million, including unfunded commitments, investment at SSLP totaled approximately $219 million. Now let me turn the call back to Michael.